I. MODIFIED AGREEMENTS

Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

Acorda Therapeutics Inc.*

Elan Corp. plc (Ireland)

Expanded license agreement giving Acorda worldwide rights to Fampridine for all indications

Elan remains responsible for formulation development and manufacturing, and could receive milestones and royalties

Affymetrix Inc. (AFFX)

BioMerieux Inc. (France)

Expanded agreement allowing BioMerieux to develop a spectrum of tests in infectious diseases and industrial settings using GeneChip technology

BioMerieux has nonexclusive access, and will pay Affymetrix an undisclosed up-front fee as well as potential milestones and royalties (10/20)

Anadys Pharmaceuticals Inc.*

Hoffmann-La Roche Inc.

Extended chemistry-based collaboration on Roche oncology program

Anadys will receive additional funding to deploy its technologies to advance Roche's lead compounds against the target; original deal was signed in August 2002 (10/2)

Chiron Corp. (CHIR)

Pfizer Inc.

Chiron acquired all of Pfizer's interest in tifacogin, a drug being developed for pneumonia

Chiron had been developing the drug in collaboration with Pharmacia, which was acquired by Pfizer; Chiron would pay Pfizer a royalty on sales (10/29)

Dendreon Corp. (DNDN)

Kirin Brewery Co. Ltd. (Japan)

Dendreon licensed to Kirin patent rights to certain HLA-DR antibodies and Kirin returned Asian rights to Dendreon's Provenge

Kirin is paying $20M to Dendreon for the HLA-DR rights and can develop products without potential patent issues; Dendreon is free to partner the cancer immunotherapy in Asia (11/14)

Evotec OAI AG (Germany; FSE:EVT)

F. Hoffmann-La Roche Ltd. (Switzerland)

Expansion of partnership through medicinal chemistry deal to identify and develop a lead for a Roche cancer target

The companies expanded their 2001 deal that was focused on production of chemical libraries; terms were not disclosed (10/22)

Gene Logic Inc. (GLGC)

Aventis SA (France)

Agreement expanding range of services Gene Logic provides to Aventis

Aventis will use toxicogenomics offerings and is first customer to use Gene Logic's gene expression data resource, the Ascenta system (10/24)

GW Pharmaceuticals plc* (UK)

Bayer AG (Germany)

Agreement to bring Sativex, GW's cannabis-based product, to the Canadian market

The deal follows a May 2003 alliance under which Bayer licensed UK rights and gained an option for other countries (11/6)

Hybrigenics SA* (France)

Group de Reserche Servier (France)

Expanded agreement for discovery of drug targets for cancer

Hybrigenics can earn milestone and royalty payments from the deal originally signed in February 2001; Servier also will make research payments (10/3)

Icagen Inc.*

Abbott Laboratories

Extension of agreement to develop small-molecules drugs that target an ion channel, for treatment of neuropathic and inflammatory pain

Renewal of the deal signed in 2001 provides for continued research and development funding by Abbott; the original deal pro-vided up-front and research payment, as well as potential milestone and royalty payments to Icagen (11/20)

Ingenium AG* (Germany)

Elan Corp. plc (Ireland)

Expanded alliance under which Ingenium will produce mouse models for Elan to use in drug target validation

The deal expands their March 2003 alli-ance, which was focused on pain manage-ment, into other areas; terms were not disclosed (10/6)

Karo Bio AB (Sweden: SSE:KARO)

Abbott Laboratories

Karo obtained rights to technologies, lead compounds and pre-clinical data resulting from the companies' diabetes collaboration

Abbott transferred rights to the program initiated in 1999 that produced the lead compound A-348441; Karo intends to continue development (11/13)

Ligand Pharmaceuticals Inc. (LGND)

Royalty Pharma AG

Ligand's selective estrogen modulators

Royalty Pharma paid $12.5M to exercise option covering three SERMs nearing completion of Phase III; Royalty Pharma gets 0.7% of the sales of the products for 10 years (10/2)

Medivir AB* (Sweden; SSE:MVIR)

F. Hoffmann-La Roche Ltd. (Switzerland)

Restructured April 2002 deal in HIV, giving Medivir respons-ibility for development of MV026048

Roche has a right to opt back into the prog-ram; if so, Medivir would be eligible for higher payments than called for in the original deal (11/19)

MGI Pharma Inc. (MOGN)

Helsinn Healthcare SA (Switzerland)

Expansion of U.S. and Canadian license agreement for Aloxi that gives MGI rights to develop the drug in additional indications and formulations

MGI is making $22.5M in initial paymentsto Helsinn and could pay another $25M in milestones based on development of Aloxi in post-operative nausea and vomiting and an oral formulation (11/17)

Protein Design Labs Inc. (PDLI)

Hoffmann-LaRoche Inc.

Restructured alliance in which PDL regains worldwide rights to Zenapax in all indications except transplantation

PDL is paying Roche $80M to revise the deal entered in 1989; PDL could repurchase transplantation rights in 2007 (9/30)

II. TERMINATED AGREEMENTS

DOV Pharmaceutical Inc. (DOVP)

Elan Corp. plc (UK)

Terminating joint venture on controlled-release formulations of bicifadine and ocinaplon

DOV is paying $5M for Elan's 17% stake, and up to $3M upon approvals (10/22)

Flamel Technoloiges SA (France; FLML)

GlaxoSmithKline plc (UK)

Terminating license agreement for sachet formulation of augmentin

The alliance using Flamel's Micropump technology will end Jan. 14, 2004 (10/20)

Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; SSE = Stockholm Stock Exchange.